Pathology providers slam government’s reckless Medicare cuts

The Federal Government’s plan to slash $356 million from Medicare rebates for pathology tests has ignited fierce opposition from the Royal College of Pathologists of Australasia (RCPA) and Australian Pathology. Experts warn the move could compromise patient care, disrupt clinical outcomes, and contradict established medical guidelines.

Set to take effect on 1 July 2025, the cuts will not only reduce funding for vitamin B12 tests but also impose new restrictions on Medicare-funded testing for vitamin B12 deficiency and urinary tract infections (UTIs). Pathologists argue these changes could have severe, unintended consequences.

“The proposed changes do not align with current clinical guidelines, which support the timely use of diagnostic testing to inform appropriate patient management,” said A/Professor Dan Owens, RCPA’s Vice President. “Limiting access to these tests may result in unintended consequences for patient outcomes.”

The RCPA has raised alarm over the impracticality of the new restrictions, which would require pathology labs to justify thousands of test orders daily – a bureaucratic nightmare that would overwhelm already stretched clinicians and pathology services.

But the implications go beyond administrative chaos. Experts fear that restricting access to UTI testing will drive up unnecessary antibiotic use, undermining national antimicrobial stewardship efforts – a critical issue for healthcare providers and policymakers alike.

Australian Pathology, representing private providers, warns that the financial squeeze on pathology services could force providers into impossible choices.

“Politicians shouldn’t be playing politics with Medicare funding. Patient rebate for pathology services has not increased since 1999. The harsh reality is that, without full and fair funding, pathology providers will be forced to make some tough decisions. The government must increase funding and stop the cuts to keep pathology bulk billed,” said a spokesperson from Australian Pathology.

As concerns mount, RCPA is calling for urgent government engagement with clinical experts to ensure policy changes don’t jeopardise patient care.

“The RCPA supports evidence-based initiatives to improve testing practices, but these changes risk compromising care,” said A/Professor Owens. “We urge the government to reconsider this approach and engage with clinical experts to ensure that any policy changes support high-quality patient care.”

In a push against the looming cuts, Australian Pathology is urging consumers to write to their local MPs, demanding an end to funding reductions and the protection of bulk billing for pathology services.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.